| ALK

Senior Manager Pharmacovigilance (m/w/d)

EasyCruit ID
3451493
Department ID
112661
Location
Expire Date
Last updated: 10.03.2025

ACARIZAX® approved in Canada for treatment of young children

Last updated: 07.03.2025

Privacy notice - shareholders, proxies and advisors

Privacy notice for shareholders, proxies and advisors

March 2025

The purpose of this privacy notice is to describe how ALK-Abelló A/S (ALK), as part of its handling of investor relations, collects, processes and stores personal data about its shareholders, proxies, and advisors, including registration in the register of shareholders and the convening and holding of Annual General Meetings. In addition, this privacy notice aims to provide information about your rights under the General Data Protection Regulation (GDPR). Your privacy is important to ALK.

1. Identity and contact details of the data controller

The legal entity responsible for processing your personal data is:

 

ALK-Abelló A/S

Address: Bøge Allé 1

2970 Hørsholm

Denmark

Tel.: +45 45747576

Email: data.protection@alk.net

 

Our Data Protection Officer:

Bech-Bruun Advokatpartnerselskab

CVR nr.: 38538071

Gdanskgade 18

2150 Nordhavn

Denmark

Tel.: +45 72 27 30 02

Email: dpo.alk@bechbruun.com

Encrypted email via: https://dpo.bechbruun.com/alk

 

If you have any questions regarding the processing of your personal data, you can always reach out to ALK or our Data Protection Officer.

2. Detailed information on the processing carried out by ALK

We process your personal data to comply with the legal obligations set out in corporate laws, as well as announcements to the Danish Financial Supervisory Authority and Nasdaq Copenhagen.

In connection with ALK’s Annual General Meeting, ALK collects, stores, and processes the personal data. This occurs in different respects, as follows:

Purpose: Identification of shareholders and maintenance of the register of shareholders, including the shareholder portal.

ALK will collect and process information about each shareholder, including:

  • Name, email address, home address
  • Portfolio of shares, voting rights, date of acquisition/sales
  • Username and password, account number with VP securities, investor ID and custodian bank

 

Lawfulness of Processing: ALK processes personal data in accordance with:

  • Article 6(1)(c) of GDPR to comply with obligations and shareholder’s rights set out in section 50 of the Danish Companies Act
  • Article 6(1)(f) of GDPR for shareholders identification to be able to answer their request and to communicate with them (legitimate interest)

 

Storage period:

ALK will retain your personal data for up to 5 years plus the current financial year after you no longer own shares in ALK.


 

Purpose: Convening and the holding of the Annual General Meetings.

ALK will process personal data to invite shareholders to the Annual General Meetings and enable them to exercise their rights at the meetings, issue proxies, and vote by post.

ALK processes personal data from shareholders' advisors so that the advisor can attend the Annual General Meeting. In addition, ALK processes this information to issue admission cards to shareholders, proxies, and advisors.

ALK will collect and process information about each shareholder, including:

  • Name, email address, home address
  • Attendance at the Annual General Meeting, advisor’s attendance at the meeting
  • Proxies, votes cast, including vote by post and portfolio of shares

 

Lawfulness of Processing: ALK processes personal data in accordance with:

  • Article 6(1)(c) of GDPR to comply with legal obligations in section 93 of the Danish Companies Act

 

Storge period:

ALK will keep your personal data for up to 5 years plus the current financial year after you no longer own shares in ALK.

The notice, including the agenda with complete proposals and certain auxiliary documents (such as, but not limited to, proxy forms and correspondence voting forms), is published as a company announcement through Nasdaq Copenhagen and on ALK’s website. It is also distributed by email to shareholders who have requested it and will remain publicly available on our website for fifteen years.

Additionally, ALK may retain the notice, agenda, and auxiliary documents for as long as necessary to protect and pursue the interests of ALK and its shareholders. Materials documenting the company’s history, decisions made, etc., are retained for as long as ALK exists.


 

Purpose: Screening of individuals subject to EU, UK, or US sanctions.

ALK is legally obligated to ensure that individuals subject to economic sanctions imposed by the European Union, the United Kingdom, or the United States of America do not exercise shareholder rights during the Annual General Meeting. To fulfil this obligation, ALK may process personal data of shareholders participating in the Annual General Meeting by screening their information against relevant sanctions lists.

ALK will process the following personal data of shareholders based on information registered in the shareholder register:

  • Name and home address

 

Lawfulness of Processing: ALK processes personal data in accordance with:

  • Article 6(1)(c) of GDPR to comply with applicable sanctions laws and regulations, which include preventing sanctioned individuals from exercising shareholder rights.
  • Article 6(1)(f) of GDPR as ALK has a legitimate interest in ensuring compliance with international sanctions regimes, maintaining corporate integrity, and mitigating legal and financial risks.

 

Storage period:

Personal data collected and processed for sanctions screening will be retained only for as long as necessary to fulfil the legal obligations and purposes stated above.


 

Purpose: Confirmation of standing for election.

Persons standing for election at the Annual General Meeting must confirm their eligibility, along with information about other managerial responsibilities.

In this context, and for the purpose of verifying the candidate’s identity and eligibility, ALK will collect and process personal data, including the candidate’s name and managerial positions held.

 

Lawfulness of Processing: ALK processes personal data in accordance with:

  • Article 6(1)(c) of GDPR to comply with Danish corporate law as set out in section 112 of the Danish Companies Act
  • Article 6(1)(f) of GDPR for processing personal data to ensure transparency in corporate governance, facilitate the election process, and enable subsequent regulatory registrations (legitimate interest)

 

Storage period:

Personal data collected and processed will be retained for as long as necessary to protect and pursue the interests of ALK and its shareholders.


 

Purpose: Submitting questions and proposals prior to the Annual General Meeting, handling of questions and exercising the right to speak at the Annual General Meeting as well as preparation of the minutes of the Annual General Meeting.

If questions are answered in writing prior to the Annual General Meeting, ALK will process your information in order to present the questions, answers, and the name of the person who submitted the question at the Annual General Meeting.

If a proposal regarding a specific issue is included on the agenda for the Annual General Meeting, ALK will process the name of the person and the proposal.

If you exercise your right to speak, your personal information will be recorded in the minutes.

Lawfulness of Processing: ALK processes personal data in accordance with

  • Article 6(1)(c) of GDPR to comply with legal obligations on section 78, 90, and 101 of the Danish Companies Act
  • Article 6(1)(f) of GDPR (legitimate interest) to be able to identify shareholders and proxies in order for them to present proposals and questions prior to and during the Annual General Meeting and to exercise their right to speak

Storage period

  • ALK will store minutes of the Annual General Meeting until it is no longer necessary for ALK to protect ALK and shareholder’s interest, including for the purpose of documenting the deliberations and resolutions passed at Annual General Meeting.

 

Purpose: Audio and/or visual recording.

General Annual Meetings are audio and/or visually recorded, and ALK may webcast the Annual General Meeting and maintain a recording on ALK’s webpage.

ALK will process your personal data, such as your voice and image, if you exercise your right to speak during the Annual General Meeting.

The recording will include the agenda (including proposals from shareholders) and may also capture questions or statements submitted in writing during the meeting.

Lawfulness of processing: ALK processes your personal data in accordance with

  • Article 6(1)(f) of GDPR (legitimate interest) in processing the recordings to use them to prepare the minutes and in documenting the proceedings at the Annual General Meeting and making it available to shareholders and media who are unable to attend or view the live webcast of the Annual General Meeting.

Storge period

  • ALK will keep a recording publicly available on demand on its website for a period of up to 5 years after the Annual General Meeting

3. Recipients of the personal data

i       ALK EMPLOYEES & EXTERNAL PROCESSORS

The recipients of your personal data will be employees of entities belonging to the ALK Group and external processors providing specific services while processing personal data on our behalf. They will receive your personal data only on a ‘need-to-know’ basis, subject to confidentiality obligations and after signing legal agreements. Furthermore, we may share your data with the general public through publication on ALK’s website in accordance with applicable law.

 

 

ii       INDEPENDENT THIRD PARTIES

When needed, we may disclose your personal data to third parties, such as Nasdaq Copenhagen A/S and Public Authorities, such as the Danish Business Authority, attorneys, or third-party auditors.

 

 

iii       TRANSFERS OF DATA FROM EU/EEA TO THIRD COUNTRIES

If we share data from the EU/EEA with a company or ALK affiliate in a third country, we will apply contractual clauses that meet EU standards to ensure the receiving company handles personal data appropriately, unless the country where the company operates is already deemed by the EU to offer an adequate level of data protection. More information about such clauses is available here. If data transfers are required in other situations, we will inform you about the specific compliance measures in place to enforce EU law.

4. Data Subject Rights

a) Right to access

     You have the right to request access to your personal data held by ALK, as well as additional details.

 

b) Right to rectification

      You have the right to request correction of inaccurate or incomplete personal data.

 

c) Right to erasure

     You have the right to request the deletion of your personal data, except when retention is required by       law.

 

d) Right to restrict processing

      You have the right to object to restriction of your personal data.

 

e) Right to object

      You have the right to object to the processing of your personal data.

 

f) Right to data portability

      In specific situations, you are entitled to receive your personal data in a structured, widely used, and        machine-readable format.

 

If you would like to exercise any of these rights, please contact us using the contact details provided in section 1.

5. Right to Complain

You have the right to file a complaint with the Data Protection Authority if you are dissatisfied with the way we process your personal data. Contact information of the Data Protection Authority can be found on their website.

If you have any questions or concerns about this privacy notice or our processing of your personal data, please contact us using the contact details provided in section 1.

Last updated: 10.03.2025

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

Last updated: 04.03.2025

FDA approves ODACTRA® for the treatment of house dust mite allergy in young children

Last updated: 27.02.2025

Testing components

Our business functions

Previous
  • Avatar

    Research and Development

    At the core of ALK, innovation thrives. Our R&D function develops world class therapies for allergy management in a collaborative environment. Fostering new insights into research, this function is shaping the future of allergy treatment.

  • Avatar

    Product Supply

    ALK's Product Supply team helps ensure smooth global delivery of allergy treatments, meeting market needs and demands, while collaborating as a dynamic and international Product Supply team

  • Avatar

    Global Quality

    In our Global Quality team, colleagues worldwide are ensuring the highest standards in product safety and efficiency, driving continuous improvements and compliance cross the organisation.

  • Avatar

    Commercial Operations

    ALK's passionate Commercial Operations team drive our international sales growth with a strong focus on our purpose to help adults and children with allergy. If you hrive in a professional sales focused environment this team is for you.

  • Avatar

    People & Organisation

    People & Organisation is a global team, driving a thriving workplace culture across borders and functions, supporting employee development, and enhancing engagement for all ALK colleagues

Next
Graph-leftGraph-right
Graph-leftGraph-right
Graph-leftGraph-right

At the core of ALK, innovation thrives. We have spent the past 100+ years pioneering within the field of allergy with the continued purpose of helping more people living with allergy.

Our deep understanding of the underlying biology and how allergy works has given us the foundation to develop a range of allergy immunotherapy treatments and management options, forming the core of our current product range. We remain committed to advancing science and are dedicated to innovate and expand our Research & Development (R&D) pipeline, continuously providing novel concepts within allergy research and treatment.

Our scientific focus is centered around respiratory allergy, food allergy, anaphylaxis and adjacent diseases areas.

Are you a young scientist making significant contributions within the field of allergy research? Apply for the prestigious Henning Løwenstein Research Award 2025 now! Deadline is 15 August 2025.


Expand scientific knowledge
Enhance the understanding of allergies and the treatments through scientific insights

Increase treatment awareness
Equip healthcare providers with the tools to effectively communicate all available treatment options to patients, facilitating informed decision-making

Continuous engagement
Establish opportunities for meaningful interactions and sustained engagement among Health Care Professionals globally, before and after the event through education

Global expertise to local impact
Facilitate broader access to events and educational activities to enrich knowledge and peer-to-peer medical collaboration
30 years of advancing allergy immunotherapy
Last updated: 02.06.2025

Governance

Animal welfare

Animal welfare is a focus throughout our research and development of new medicines. ALK conducts animal testing to ensure its medicines are safe and effective, using animals only when alternative models are insufficient. The ´three R’s: replace, reduce and refine´ philosophy guides our strategy.

Whistleblowing protection

Promoting a culture of transparency and accountability, ALK encourages employees, suppliers, vendors, consultants or others with a work-related relationship with ALK to raise serious and sensitive concerns using our whistleblower hotline, ALK Alertline.

ALK Alertline
ALK's whistleblower hotline enables employees, business partners and other stakeholders to report any serious and sensitive concern in a confidential and anonymous manner.
Code of Conduct
ALK's Code of Conduct outlines the standards of behaviour that we expect from all ALK employees when interacting with stakeholders.

Prevention and detection of corruption and bribery

ALK has zero-tolerance for employees engaging in any corrupt activities, as outlined in our anti-corruption policy. We regularly assess risks and adjust our compliance program accordingly. To proactively prevent corruption and bribery events, online training in the company´s Code of conduct is delivered annually to all employees globally.

Code of Conduct
Anti-corruption Policy
Data Ethics Policy
Third party code of conduct
Tax policy
Whistleblower Policy
UK Modern Slavery Act statement 2024

Partnering for sustainability

The challenges of climate change require commitments and partnerships

Last updated: 24.03.2025

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

Last updated: 21.02.2025

Annual General Meeting in ALK-Abelló A/S on 13 March 2025

Last updated: 19.02.2025

Social

Own workforce

Employee engagement

Our commitment to fostering a culture of open communication and collaboration is exemplified through our annual global engagement survey results. This year's participation rate remained high at 95%, reflecting the Executive Leadership Team's commitment to valuing employee feedback and taking action. The overall engagement score was 8.3, positioning ALK in the top 5% against the international healthcare benchmark.

Health and safety

Health and safety management is an essential part of ALK’s operations, especially in production and farming activities where employees may face workplace risks.

1 2022 and 2023 figures are not covered by the Independent Auditor’s limited assurance report on the Sustainability Statement

Regular safety dialogues with workers councils or employees
This collaborative approach ensures that the perspectives of our employees are considered in the development and improvement of safety policies and procedures.
Monthly safety inspections across all production facilities
Identifies and addresses potential hazards, and encourages employees to report near misses, allowing us to implement corrective measure and improve safety protocols where needed.
Digitalisation of near miss frequency reporting
Near misses are invaluable opportunities to identify potential hazards and prevent accidents before they occur.

Non-discrimination/inclusion

Embracing a multi-dimensional perspective, we acknowledge diversity in terms of physical, psychological, social, lifestyle, and cognitive dimensions, actively engaging with a number of employee focus groups to seek input on improving inclusion across ALK. Furthermore, ALK tracks employees’ perceptions of diversity and inclusion and their sense of psychological safety via the annual employee engagement survey. In 2024, the overall perception of D&I in ALK is 8.4, which is 0.2 points above the industry benchmark.

Employee engagement

Recognising the pivotal role of development in enhancing employee retention and performance, ALK seeks to foster a culture of continuous learning and growth for its workforce. Development agreements are integrated as a fundamental component of our annual people processes for all employees to gain a clear direction for their learning and growth opportunities as part of the Global People Performance Process.

Value chain workers

ALK's Third-party Code of Conduct outlines the standards of behavior that we expect from all third parties globally when it comes to business conduct and treatment of employees. The Third-party Code of Conduct is an integrated part of our GxP (good practice) supplier agreements.

To address supplier risk, we utilize an external supplier evaluation platform to identify environment, labor & human rights, and procurement risks. 400+ suppliers approved for our GxP processes have been screened, none of which have been identified as high-risk.

Consumers and end users

Helping more people with allergies is at the core of ALK. We aim to support 5 million allergy patients by 2030 to advance our positive impact. In 2024, ALK reached an estimated 2.6 million patients in treatment, as a result of its commercial activities.

1Due to the lack of comprehensive data across all markets, directly measuring the number of patients treated with ALK products is not possible. Estimates are made using various data sources, an in-house Patient Model, and insurance claims data, but this involves assumptions that introduce uncertainty. The use of this datapoint is considered significant.

Safety of people with allergies

ALK has a rigorous safety reporting system in place ensuring that safety data from any source, including clinical trials, are collected and analysed systematically by our global pharmacovigilance team. This ensures that the safety profile of our products is optimized for the benefit of users, and that the relevant authorities can be made aware of any safety issue arising from our products to facilitate immediate action.

Education of healthcare professionals

We engage systematically in educational activities, training and dialogue with healthcare professionals to elevate the standard of care in allergy diagnosis and treatment. Much of our engagement is done digitally enabling us to reach more healthcare professionals and reduce our climate impact.

Policy downloads

Code of conduct
Diversity and Inclusion Policy
UK Modern Slavery Act statement 2024
Access to Medicine
Third Party Code of Conduct

Partnering for sustainability

The challenges of social action require commitments and partnerships.

Last updated: 24.03.2025